Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02509481 · ClinicalTrials.gov registry record · Phase 2
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
A Phase 2 study, sponsored by Colorado State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,712
- Enrollment target
NCT02509481 is a Phase 2 study that has completed, run by Colorado State University. The registered enrollment target is 2,712 participants.
The verdict
NCT02509481, a Phase 2 study, has completed, sponsored by Colorado State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,712 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three week intervals over the rainy-season, is well-tolerated and safe, and also effective in reducing local malaria transmission and thus clinical malaria episodes in treated village children.
Interventions
- DRUG Ivermectin
- DRUG Albendazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,712 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02509481
The ClinicalTrials.gov registry entry for NCT02509481 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2,712 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Colorado State University, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ivermectin is the first listed.
NCT02509481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02509481 about?
NCT02509481 is a clinical study titled "Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study". The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three week intervals over the rainy-season, is well-tolerated and safe, and also effective in reducing local malaria transmission and thus clinical malaria episodes in...
What is the current status of trial NCT02509481?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,712 participants. The study started on 2015-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02509481?
The interventions under investigation include: Ivermectin (DRUG), Albendazole (DRUG).
Who is sponsoring clinical trial NCT02509481?
This trial is sponsored by Colorado State University, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.